Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology
RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.
Medical Devices & Diagnostics
Pharma & Biotech
Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished
Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.
Pharma & Biotech
Why Cartography Biosciences’ Phase 1 colorectal cancer trial matters after Samsung Ventures backing
Samsung wants oncology optionality beyond manufacturing. Cartography’s Phase 1 T-cell engager puts platform biology under pressure.
Pharma & Biotech
How CPTx is positioning targeted lipid nanoparticles at the center of CAR T innovation
Explore how CPTx’s targeted lipid nanoparticle platform could reshape CAR T therapy scalability and access. Read the full analysis now.
Pharma & Biotech
How Arvinas and Pfizer’s VEPPANU approval tests the commercial future of PROTAC drugs
Arvinas Inc., with partner Pfizer Inc., has received U.S. Food and Drug Administration approval for VEPPANU, also known as vepdegestrant, for adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer after disease progression following at least one line of endocrine therapy. The approval gives the oncology market its
Medical Devices & Diagnostics
Pharma & Biotech
Merck KGaA just made a quiet digital-health move. Could hybrid drugs be pharma’s next big reset?
Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.
Pharma & Biotech
Merck’s Terns deal clears antitrust hurdle as TERN-701 becomes bigger oncology test
Merck cleared one deal hurdle. TERN-701 still has to prove whether chronic myeloid leukemia can justify a $6.7 billion bet.
Pharma & Biotech
Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.
CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.
Pharma & Biotech
Can Whitehawk Therapeutics turn preclinical ADC depth into a real oncology pipeline advantage?
Whitehawk Therapeutics unveiled AACR 2026 data for three ADCs. Read what it means for pipeline differentiation, risk, and investor sentiment.
Pharma & Biotech
Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?
Byondis is showcasing two new ADC technology platforms at AACR 2026. Read why antifolate and phosphonate payloads could reshape oncology innovation.